Literature DB >> 29431040

Can Patients Afford to Be Adherent to Expensive Oral Cancer Drugs?: Unintended Consequences of Pharmaceutical Development.

Tisha M Felder, Charles Lee Bennett.   

Abstract

Entities:  

Year:  2013        PMID： 29431040      PMCID： PMC3825169          DOI： 10.1200/JOP.2013.001167

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.840


× No keyword cloud information.
  15 in total

1.  Cancer therapy costs influence treatment: a national survey of oncologists.

Authors:  Peter J Neumann; Jennifer A Palmer; Eric Nadler; Chihui Fang; Peter Ubel
Journal:  Health Aff (Millwood)       Date:  2010 Jan-Feb       Impact factor: 6.301

2.  Forgoing medical care because of cost: assessing disparities in healthcare access among cancer survivors living in the United States.

Authors:  Kathryn E Weaver; Julia H Rowland; Keith M Bellizzi; Noreen M Aziz
Journal:  Cancer       Date:  2010-07-15       Impact factor: 6.860

Review 3.  Patient navigation: an update on the state of the science.

Authors:  Electra D Paskett; J Phil Harrop; Kristen J Wells
Journal:  CA Cancer J Clin       Date:  2011-06-09       Impact factor: 508.702

4.  The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.

Authors: 
Journal:  Blood       Date:  2013-04-25       Impact factor: 22.113

Review 5.  What is the evidence for pharmaceutical patient assistance programs? A systematic review.

Authors:  Tisha M Felder; Nynikka R Palmer; Lincy S Lal; Patricia Dolan Mullen
Journal:  J Health Care Poor Underserved       Date:  2011-02

6.  Cancer patients' use of pharmaceutical patient assistance programs in the outpatient pharmacy at a large tertiary cancer center.

Authors:  Tisha M Felder; Lincy S Lal; Charles L Bennett; Frank Hung; Luisa Franzini
Journal:  Community Oncol       Date:  2012-02-10

7.  Risk factors for financial hardship in patients receiving adjuvant chemotherapy for colon cancer: a population-based exploratory analysis.

Authors:  Veena Shankaran; Sanjay Jolly; David Blough; Scott D Ramsey
Journal:  J Clin Oncol       Date:  2012-03-12       Impact factor: 44.544

Review 8.  Cancer insurance policies in Japan and the United States.

Authors:  C L Bennett; P D Weinberg; J J Lieberman
Journal:  West J Med       Date:  1998-01

9.  Medication nonadherence: a diagnosable and treatable medical condition.

Authors:  Zachary A Marcum; Mary Ann Sevick; Steven M Handler
Journal:  JAMA       Date:  2013-05-22       Impact factor: 56.272

10.  Drug company-sponsored patient assistance programs: a viable safety net?

Authors:  Niteesh K Choudhry; Joy L Lee; Jessica Agnew-Blais; Colleen Corcoran; William H Shrank
Journal:  Health Aff (Millwood)       Date:  2009 May-Jun       Impact factor: 6.301
View more
  4 in total

1.  Patient, provider, and hospital factors associated with oral anti-neoplastic agent initiation and adherence in older patients with metastatic renal cell carcinoma.

Authors:  Deborah R Kaye; Lauren E Wilson; Melissa A Greiner; Lisa P Spees; Jessica E Pritchard; Tian Zhang; Craig E Pollack; Daniel George; Charles D Scales; Chris D Baggett; Cary P Gross; Michael S Leapman; Stephanie B Wheeler; Michaela A Dinan
Journal:  J Geriatr Oncol       Date:  2022-02-04       Impact factor: 3.929

2.  Why individual-level interventions are not enough: Systems-level determinants of oral anticancer medication adherence.

Authors:  Lorraine T Dean; Marshalee George; Kimberley T Lee; Kimlin Ashing
Journal:  Cancer       Date:  2020-05-21       Impact factor: 6.860

3.  Cost Savings Analysis of Individualized Exercise Oncology Programs.

Authors:  Karen Y Wonders; Rob Wise; Danielle Ondreka; Josh Gratsch
Journal:  Integr Cancer Ther       Date:  2019 Jan-Dec       Impact factor: 3.279

4.  Health services utilization, out-of-pocket expenditure, and underinsurance among insured non-elderly cancer survivors in the United States, 2011-2015.

Authors:  Mohammad A Karim; Amit G Singal; Robert L Ohsfeldt; Michael A Morrisey; Hye-Chung Kum
Journal:  Cancer Med       Date:  2021-07-30       Impact factor: 4.452
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.